还原型谷胱甘肽治疗中、重度慢性乙型肝炎的疗效和安全性研究

目的评价还原型谷胱甘肽治疗中、重度慢性乙型肝炎的疗效和安全性。方法将120例中、重度慢性乙型肝炎患者随机分为2组，治疗组应用还原型谷胱甘肽注射液1800mg，每天静脉点滴1次;对照组应用门冬氨酸钾镁30ml，每天静脉点滴1次，疗程均为4周。观察患者临床表现、生化指标和不良事件发生的情况。结果治疗组患者的乏力有效率为883％（53/60）．纳差的有效率为85％（51／60）．与对照组比较，差异有统计学意义（P〈005）。治疗组患者的血清ALT．AST．血清总胆红素（T刚）的降幅高于对照组（P〈005）．白蛋白（ALB）治疗后增高，与对照组比较，差异有统计学意义（P〈005）。ALT、AST的复常率治疗组分别为746％和765％，对照组分别为655％和688％，差异有统计学意义（P〈005）。2组均未发现明显的不良反应。结论还原型谷胱甘肽能显著改善中、重度慢性乙型肝炎的临床症状和肝功能指标，不良反应少且轻微。

Clinical study of efficacy and safety of reduced glutathione treating midrange and severity chronic hepatitis B

Objective To evaluate the efficacy and safety of reduced glutathione in the treatment of midrange and severity chronic hepatitis B. Methods 120 patients with midrange and severity chronic hepatitis B were randomly divided into the treatment group and control group. In the treatment group, patients were intravenous injected with glutathione 1800 mg qd; in the control group, patients were intravenous injected with potassium magnesium aspartate 30ml qd. The period of treatment was 4 weeks. Results In the treatment group, the effective rate of fatigne and anorexia were 88.3% and 85%, which were significantly higher than that in the control group (P<0.05). ALT,AST and TBil were lower in the treatment group (P<0.05). The increase of albumin after treatment was more significant in the treatment group than in the control group (P<0.05). Severe adverse drug reactions of both groups were not discovered. Conclusion Reduced glutathione can improve the symptom and the liver function index, its adverse effect is rare and light.